Modality
ASO
MOA
HER2
Target
SGLT2
Pathway
Wnt
Urothelial CaPSP
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
~Jan 2022
→ ~Apr 2023
Phase 2
Jul 2023
→ Jan 2028
Phase 2Current
NCT08064770
2,681 pts·Urothelial Ca
2023-07→2028-01·Active
2,681 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-051.8y awayPh3 Readout· Urothelial Ca
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Active
Catalysts
Ph3 Readout
2028-01-05 · 1.8y away
Urothelial Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08064770 | Phase 2/3 | Urothelial Ca | Active | 2681 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |